The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Place your bets? Swing high swing low?
Either way LT £18-£20
Results may move SP at end Feb
Up 20% trim down 20% add - add & trim no brainers to lower averages.
(Sharecast News) - RBC Capital Markets has reiterated its 'outperform' rating on Smith & Nephew ahead of the medical devices giant's fourth-quarter results later this month, saying it sees upside risk to current estimates.
Strong results from sector peers like Johnson & Johnson, Stryker and Zimmer Biomet suggest that the global hip and knee market expanded by a combined 7.1% in the fourth quarter, as surgery levels increased on the back of a "a return to normal phasing and secular growth in demand", RBC said.
"If Smith & Nephew's Ortho revenues have grown in line with the market, this implies up to 1% upside to Q4 group sales vs RBCe/consensus, or more if it takes share."
Meanwhile, Stryker and Zimmer Biomet also provided strong guidance for 2024 that was ahead of consensus forecasts on both revenues and profits, which could bode well for Smith & Nephew, RBC said.
"We think there is a meaningful chance that management guides to 5-7% growth in FY2024, implying c1% upside to consensus at the midpoint. Higher revenue growth would de-risk consensus forecasts for trading margin (currently 18.4%), which depends largely on operating leverage on volumes," the broker said.
Smith & Nephew's shares have underperformed the wider sector by 10% so far in 2024, which could reflect "nervousness" around hitting margin guidance, RBC said. So the reaction to a strong fourth-quarter result could be strong.
"We also remain bullish on SN in the longer term, and continue to believe its valuation vs peers does not account for its competitive positioning or growth outlook."
The broker has a 1,500p target price for the stock, which was up 0.3% at 1,096p by 0855 GMT.
Hardman & Co
Smith & Nephew (SN.) has, generally, been a weak performer in 2023. Although there was an uplift in the shares following the reporting of 2022 results, the stock faced corrections after reporting 1Q’23 and 1H’23 results, since when there has been a modest recovery. I am surprised that the perennial (every year for >30 years!!) acquisition rumours did not re-ignite when it hit its low point in October.
My insurance policy for all my ortho needs in the not too distant future :)
Will I get £20 per share before I become a customer? Key question imv.
My target is £16-18 :) but 1320 would be a start. Waiting for an up £2 day with SN. - so overdue.
Bank of America raises Smith & Nephew price target to 1,320 (1,180) pence - 'buy'
Smith & Nephew Plc
10 January 2024
Smith+Nephew completes acquisition of novel cartilage regeneration technology for sports medicine knee repair
10 January 2024
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces that it has completed the acquisition of CartiHeal, developer of
Agili-C, a novel sports medicine technology for cartilage regeneration in the knee.
Agili-C is an off-the-shelf one-step treatment for osteochondral (bone and cartilage) lesions with a broader indication than existing treatments. It is indicated to treat a wide patient population, including those with lesions in knees with mild to moderate osteoarthritis, a previously unaddressed condition, as well as the approximately 700,000 patients1 that receive cartilage repair annually in the US.
"With its proven superiority2 to current standard of care, Agili-C has the potential to transform cartilage repair outcomes," said Scott Schaffner, President Sports Medicine, Smith+Nephew. "Our expertise in regenerative therapy and leadership in knee repair gives me great confidence that this will be a significant value creator for Smith+Nephew."
Smith+Nephew paid $180 million on completion, with up to a further $150 million contingent on future financial performance, as previously disclosed.
FY results due mid Feb (20th). May the force be with you.
Patience with this one - when it plunges I add and release when it rises and that brings the average cost down nicely
Tipped by several 'experts' and economists but has done nothing to the share price.
Inve5t
Investor & speculator are not mutually exclusive.
🎅 Merry Christmas and GL, especially with BOO recovery. I have speculated on that one too.
Simply posting the city am news. London is so undervalued and many stocks could be bid targets.
That is news enough for me not to be out of certain stocks.
When the bid frenzy starts or the tipsters speculate, the year end New Year, Jan rally with provide an upside floating all boats.
Very important all in all.
SN. is a core holding for many. I am looking £20+ for mine.
Why is this important and may posts such as these. Your can either be a speculator or an investor, investors don’t jump up and down praying for a takeover, investors are long term owners who are more than happy to ride the sp dips and happy for a company to have a plan for long term growth.
Https://www.cityam.com/private-equity-firms-line-up-london-lawyers-ahead-of-deals-frenzy/
Interestingly specific prognostication, StockReady ... :D
Why do you think this? (I hope you're right!)
I think we are now in a position with big fuel charge in the tank to go all the way up to £ 15 to £18 range and can happen within the next 5 to 8 months
This will start moving from second week of December
Watch the space
GLA
IMHO
Goldman,on the case
https://www.proactiveinvestors.co.uk/companies/news/1032776/smith-nephew-s-underperformance-set-to-change-says-goldman-1032776.html
Https://www.proactiveinvestors.co.uk/companies/news/1031980/smith-nephew-downgrade-cycle-coming-to-an-end-1031980.html
looks like the downtrend......is ending
Good News for this Company. Future should be more bright re Medical business under Labour. Conservatives created the demand.